# Filing Detail

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001628280-25-007715
Filing Date
2025-02-25
Accepted
2025-02-25 16:02:49
Documents
111
Period of Report
2024-12-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-K | bcrx-20241231.htm iXBRL | 10-K | 2177984
2 | EX-10.50 | bcrx-20241231xex10_50.htm | EX-10.50 | 13660
3 | EX-19 | insidertradingpolicy.htm | EX-19 | 63011
4 | EX-21 | bcrx-20241231xex21.htm | EX-21 | 9803
5 | EX-23 | bcrxfy24formconsentxex23.htm | EX-23 | 6706
6 | EX-31.1 | bcrx-20241231xex311.htm | EX-31.1 | 9749
7 | EX-31.2 | bcrx-20241231xex312.htm | EX-31.2 | 9746
8 | EX-32.1 | bcrx-20241231xex321.htm | EX-32.1 | 6019
9 | EX-32.2 | bcrx-20241231xex322.htm | EX-32.2 | 5515
15 |  | bcrx-20241231_g1.jpg | GRAPHIC | 118381
| Complete submission text file | 0001628280-25-007715.txt |  | 11479410

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
10 | XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT | bcrx-20241231.xsd | EX-101.SCH | 78890
11 | XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT | bcrx-20241231_cal.xml | EX-101.CAL | 101258
12 | XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT | bcrx-20241231_def.xml | EX-101.DEF | 327812
13 | XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT | bcrx-20241231_lab.xml | EX-101.LAB | 896407
14 | XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT | bcrx-20241231_pre.xml | EX-101.PRE | 636016
114 | EXTRACTED XBRL INSTANCE DOCUMENT | bcrx-20241231_htm.xml | XML | 1653391

Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 000-23186 | Film No.: 25662920
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)